目的探讨抗甲状腺药物(atd)引起粒细胞缺乏症的临床特点，治疗及转归。
Objective to investigate the clinical character, treatment and prognosis of agranulocytosis induced by anti-thyroid drug (ATD).
抗甲状腺药物影响131i疗效的机理可能在于改变了131i的有效半衰期和(或)甲状腺对131i的摄取率。
Antithyroid drugs may influence the efficacy of 131i, the possible mechanism might be that antithyroid drugs change the effective half-time and (or) uptake of 131i.
在接受抗甲状腺药物(atd)治疗的突眼性甲状腺肿615例患者中，215例(34.9%)发生毒性反应。
Out of 615 patients with Graves' disease who accepted the treatment of antithyroid drugs (ATD), 215 (34.9%) developed toxic effects of the drugs.
指出同位素治疗甲亢初期应服用抗甲状腺药物，讨论了淡漠型危象的有关问题。
We suggest that thyroid drugs should be given concurrently with radioactive iodine to treat early hyperthyroidism. The problems concerning apathetic thyroid crisis are also discussed.
指出同位素治疗甲亢初期应服用抗甲状腺药物，讨论了淡漠型危象的有关问题。
We suggest that thyroid drugs should be given concurrently with radioactive iodine to treat early hyperthyroidism. The problems concerning apathetic thyroid crisis are also discussed.
应用推荐